EA033130B1 - Способы и композиции для улучшения когнитивной функции - Google Patents

Способы и композиции для улучшения когнитивной функции

Info

Publication number
EA033130B1
EA033130B1 EA201170571A EA201170571A EA033130B1 EA 033130 B1 EA033130 B1 EA 033130B1 EA 201170571 A EA201170571 A EA 201170571A EA 201170571 A EA201170571 A EA 201170571A EA 033130 B1 EA033130 B1 EA 033130B1
Authority
EA
Eurasian Patent Office
Prior art keywords
levetiracetam
subject
pharmaceutically acceptable
acceptable salt
cognitive function
Prior art date
Application number
EA201170571A
Other languages
English (en)
Russian (ru)
Other versions
EA201170571A1 (ru
Inventor
Михела Галлахер
Ребекка Хаберман
Мин Тен Кох
Original Assignee
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Джонс Хопкинс Юниверсити filed Critical Дзе Джонс Хопкинс Юниверсити
Publication of EA201170571A1 publication Critical patent/EA201170571A1/ru
Publication of EA033130B1 publication Critical patent/EA033130B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201170571A 2008-10-16 2009-10-16 Способы и композиции для улучшения когнитивной функции EA033130B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10584708P 2008-10-16 2008-10-16
US15263109P 2009-02-13 2009-02-13
US17553609P 2009-05-05 2009-05-05
PCT/US2009/005647 WO2010044878A1 (en) 2008-10-16 2009-10-16 Methods and compositions for improving cognitive function

Publications (2)

Publication Number Publication Date
EA201170571A1 EA201170571A1 (ru) 2011-12-30
EA033130B1 true EA033130B1 (ru) 2019-08-30

Family

ID=41403972

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170571A EA033130B1 (ru) 2008-10-16 2009-10-16 Способы и композиции для улучшения когнитивной функции

Country Status (12)

Country Link
US (5) US20100099735A1 (enExample)
EP (2) EP3260118B1 (enExample)
JP (3) JP5917148B2 (enExample)
CN (2) CN107243007A (enExample)
AU (1) AU2009303834B2 (enExample)
BR (1) BRPI0920342A2 (enExample)
CA (1) CA2740610C (enExample)
DK (2) DK2346500T3 (enExample)
EA (1) EA033130B1 (enExample)
ES (2) ES2865504T3 (enExample)
HK (1) HK1245099A1 (enExample)
WO (1) WO2010044878A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0920342A2 (pt) 2008-10-16 2020-06-23 The Johns Hopkins University Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
EP2672822A4 (en) * 2011-02-09 2014-08-27 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP2968257A4 (en) * 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP3590506A1 (en) * 2015-05-22 2020-01-08 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
ES3015257T3 (en) * 2016-05-20 2025-04-30 Pasteur Institut Levetiracetam, brivaracetam or selectracetam for use in treating sepsis induced acute brain dysfunction
US10370561B2 (en) 2016-06-28 2019-08-06 Prc-Desoto International, Inc. Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof
US11098222B2 (en) 2018-07-03 2021-08-24 Prc-Desoto International, Inc. Sprayable polythioether coatings and sealants
CN109892247B (zh) * 2019-04-19 2023-08-18 桂林医学院 一种猫参与的检测大鼠认知功能的实验装置
WO2021063414A1 (zh) * 2019-09-30 2021-04-08 厦门大学 戊酸衍生物在治疗唐氏综合征中的应用
IL299754A (en) * 2020-07-10 2023-03-01 Agenebio Inc Combinations of gaba alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886023A (en) * 1991-05-02 1999-03-23 Daiichi Pharmaceutical Co., Ltd. Agent for improving dementia
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US20080076820A1 (en) * 2001-08-22 2008-03-27 Eiichi Otomo Method for treating neurodegeneration
WO2009109547A1 (en) * 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
IT1045043B (it) * 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
IT1075280B (it) * 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
EP0005689B1 (fr) * 1978-05-08 1981-03-18 U C B, S.A. Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4372960A (en) * 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
IL67623A (en) * 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JPS6222785A (ja) * 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
IT1190133B (it) * 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3709230A1 (de) * 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
JPS6422883A (en) * 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
CA2007732A1 (en) 1989-01-17 1990-07-17 Gary L. Olson Cyclohexaneacetamide derivatives
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US5439930A (en) * 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5440023A (en) * 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
IT1285801B1 (it) * 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
US6131106A (en) * 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
TWI238062B (en) 1999-12-01 2005-08-21 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
EP1356812B1 (en) * 2000-12-28 2009-05-13 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
EP1379236A4 (en) * 2001-02-23 2009-01-21 Ucb Sa TREATMENT OF TICS, TREMOR AND RELATED DISORDER
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
AU2002335015B8 (en) 2001-10-16 2006-11-30 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
ITMI20030573A1 (it) * 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
ES2323313T3 (es) * 2003-12-02 2009-07-13 Ucb Pharma, S.A. Derivados de imidazol, procedimientos para prepararlos y sus usos.
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
EP1758855B1 (en) 2004-06-11 2007-11-21 UCB Pharma, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
MX2007009088A (es) * 2005-01-27 2007-09-13 Alembic Ltd Formulacion de liberacion extendida de levetiracetam.
AU2006228947A1 (en) * 2005-03-30 2006-10-05 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
WO2006128693A2 (en) 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
CA2631885A1 (en) 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) * 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
WO2008132142A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
WO2009038412A2 (en) 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
BRPI0920342A2 (pt) 2008-10-16 2020-06-23 The Johns Hopkins University Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
US9125898B2 (en) * 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
AU2009317280B2 (en) 2008-11-18 2014-03-06 Ucb Pharma, S.A. Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
CA2747396C (en) 2009-01-29 2015-12-08 Serge Cuypers Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886023A (en) * 1991-05-02 1999-03-23 Daiichi Pharmaceutical Co., Ltd. Agent for improving dementia
US20080076820A1 (en) * 2001-08-22 2008-03-27 Eiichi Otomo Method for treating neurodegeneration
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
WO2009109547A1 (en) * 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"P.5.017 Use of valproate in treatment of behavioural and psychological disturbances of dementia", EUROPEAN NEUROPSYCHOPHARMACOLOGY., ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM., NL, vol. 15, 1 January 2005 (2005-01-01), NL, pages S565, XP025327109, ISSN: 0924-977X *
LIPPA CAROL; REVUELTA GONZALO; GLIEBUS GEDIMINAS; IRWIN DAVID; TOWNSHIP HADDON; HEPLER MARJORIE; ROSSO ANDREA: "Levetiracetam: Seizure management for elderly patients with cognitive impairment", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 70, no. 11, suppl. 1, 11 March 2008 (2008-03-11), US, pages A97, XP009127253, ISSN: 0028-3878 *
MARINI G; CARATTI C; PELUFFO F; CELASCO G; GASPARRO M G: "PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF PRAMIRACETAM CI-879 IN THE TREATMENT OF ELDERLY SUBJECTS WITH MEMORY IMPAIRMENT", ADVANCES IN THERAPY., HEALTH COMMUNICATIONS, METUCHEN, NJ., US, vol. 9, no. 3, 1 January 1992 (1992-01-01), US, pages 136 - 146, XP009127252, ISSN: 0741-238X *
ROZZINI R; ZANETTI O; BIANCHETTI A: "Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.", ACTA NEUROLOGICA, CHIRURGIA, NAPLES, IT, vol. 15, no. 1, 1 February 1993 (1993-02-01), IT, pages 44 - 52, XP009127254, ISSN: 0001-6276 *

Also Published As

Publication number Publication date
CA2740610C (en) 2020-01-07
JP2012505883A (ja) 2012-03-08
AU2009303834B2 (en) 2016-08-11
AU2009303834A1 (en) 2010-04-22
JP2016147915A (ja) 2016-08-18
EP3260118A1 (en) 2017-12-27
CA2740610A1 (en) 2010-04-22
DK3260118T3 (da) 2021-04-19
US20100099735A1 (en) 2010-04-22
EP2346500B1 (en) 2017-05-17
JP6271641B2 (ja) 2018-01-31
US20150094352A1 (en) 2015-04-02
JP5917148B2 (ja) 2016-05-11
US20220218665A1 (en) 2022-07-14
BRPI0920342A2 (pt) 2020-06-23
HK1245099A1 (zh) 2018-08-24
ES2637497T3 (es) 2017-10-13
US8604075B2 (en) 2013-12-10
DK2346500T3 (en) 2017-07-17
CN107243007A (zh) 2017-10-13
US20120046336A1 (en) 2012-02-23
JP2014169339A (ja) 2014-09-18
EA201170571A1 (ru) 2011-12-30
CN102227217A (zh) 2011-10-26
HK1248543A1 (en) 2018-10-19
WO2010044878A1 (en) 2010-04-22
EP2346500A1 (en) 2011-07-27
EP3260118B1 (en) 2021-03-24
US20240293363A1 (en) 2024-09-05
ES2865504T3 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
EA033130B1 (ru) Способы и композиции для улучшения когнитивной функции
GEP20125565B (en) Lactam compounds and their pharmaceutical use
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
WO2007112000A3 (en) Treatment of pain
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
ATE417832T1 (de) Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
ATE473742T1 (de) Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
WO2008075376A8 (en) Polymorphic forms of bortezomib and process for their preparation
HRP20050262A2 (en) Pyrrolidone derivatives as maob inhibitors
MA30296B1 (fr) Nouvelles amines
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
DE602004015089D1 (de) Pyrroloimidazolderivate ,verfahern zu ihrer herstellung, diese enthaltende zusammensetzungen, und ihre verwendung als nootropika
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
EA200600316A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗУЕМЫЕ В НЕМ ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG MD TJ TM